Electronic Medical Record Alerts to Optimize Medical Therapy in Heart Failure and Reduced Ejection Fraction

Electronic Medical Record Alerts to Optimize Medical Therapy in Heart Failure and Reduced Ejection Fraction in a Low-middle Income Country

NCT06166823•Instituto Cardiovascular de Buenos Aires

View on ClinicalTrials.gov

Summary

OPTIMAL-HF is a pragmatic, cluster randomized, single-blind intervention trial that will be conducted at an outpatient clinic in Argentina. The trial will assess the effectiveness of an individualized-based alert system compared to usual care in improving GDMT optimization at 90 days in patients with HFrEF.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients
•Eligible patients will include those with an EF ≤ 40% on their most recent echocardiogram, age \> 18, and an outpatient cardiology encounter during the study period.
•Age 18 or over
•Cardiologists from an outpatient clinic at a cardiovascular center in Buenos Aires will be selected for potential participation in the study.

Exclusion Criteria

•under optimal medical treatment
•palliative care, or undergoing hemodialysis will be excluded
•Cardiologist

Key Dates

Start Date

January 15, 2024

Primary Completion Date

December 15, 2024

Completion Date

January 1, 2025

Last Updated

December 12, 2023

Enrollment

240

ESTIMATED participants

Conditions

HFrEF - Heart Failure With Reduced Ejection Fraction

Interventions

EMR alert

OTHER

Contacts

Lucrecia Burgos, MD

CONTACT

47508700 lburgos@icba.com.ar

Effect of Vericiguat on cardiAc Remodeling in Patients With Heart faiLure and Reduced Ejection fractioN (HFrEF): A Prospective sTudy usIng NOvel Echocardiographic Imaging Techniques (VALENTINO)

NCT07472595

HFrEF - Heart Failure With Reduced Ejection Fraction

View study

NOT_YET_RECRUITINGPHASE3

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

NCT00610051

End Stage Cardiac FailureHFrEF - Heart Failure With Reduced Ejection Fraction+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Electronic Medical Record Alerts to Optimize Medical Therapy in Heart Failure and Reduced Ejection Fraction

Inclusion Criteria

Exclusion Criteria

Effect of Vericiguat on cardiAc Remodeling in Patients With Heart faiLure and Reduced Ejection fractioN (HFrEF): A Prospective sTudy usIng NOvel Echocardiographic Imaging Techniques (VALENTINO)

ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients with Heart Failure